Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Opus Genetics (IRD) EBIAT (2020 - 2026)

Opus Genetics has reported EBIAT over the past 12 years, most recently at -$65.5 million for Q1 2026.

  • Quarterly EBIAT fell 699.79% to -$65.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$106.9 million through Mar 2026, down 82.42% year-over-year, with the annual reading at -$49.6 million for FY2025, 13.8% up from the prior year.
  • EBIAT was -$65.5 million for Q1 2026 at Opus Genetics, down from -$16.5 million in the prior quarter.
  • Over five years, EBIAT peaked at $33.9 million in Q4 2022 and troughed at -$65.5 million in Q1 2026.
  • The 5-year median for EBIAT is -$7.1 million (2024), against an average of -$9.7 million.
  • Year-over-year, EBIAT surged 637.64% in 2022 and then crashed 699.79% in 2026.
  • A 5-year view of EBIAT shows it stood at $33.9 million in 2022, then plummeted by 114.13% to -$4.8 million in 2023, then tumbled by 632.74% to -$35.1 million in 2024, then skyrocketed by 52.97% to -$16.5 million in 2025, then tumbled by 296.63% to -$65.5 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's EBIAT are -$65.5 million (Q1 2026), -$16.5 million (Q4 2025), and -$17.5 million (Q3 2025).